Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Long-Term Investors Should Buy a Small Amount of Nio Stock on Weakness

By Larry Ramer, InvestorPlace Contributor

At this point, BlackBerry is much more attractive than Nio stock for long-term investors

4 Overvalued Stocks to Leave Out of a Portfolio

By Larry Ramer, InvestorPlace Contributor

Disney, Fisker, Lordstown and Virgin Galactic all have overvalued stocks because their risk levels and valuations are far too elevated.

Tattooed Chef Stock Looks Better Than It Did, but It’s Still Overvalued

By Larry Ramer, InvestorPlace Contributor

Tattoo Chef is making the right moves, and TTCF stock has become more appetizing. But the shares aren't a buy yet.

Sell Ocugen Stock Now Before It Sinks Even Further

By Larry Ramer, InvestorPlace Contributor

Biden's decision to buy 100 million more of Johnson & Johnson's vaccine, along with the potential of herd immunity, makes OCGN stock a sell.

Addressable Market Aside, Bionano Stock Is a Buy on Innovation Alone

By Larry Ramer, InvestorPlace Contributor

Bionano's Saphyr system looks poised to revolutionize diagnostics and medical research, making BNGO stock worth buying for long-term investors.

Load More